The Evolving Science and Medicine of Cardioprotection in Type 2 Diabetes

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period November 28, 2011 through November 28, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

2.5 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in cardiovascular risk reduction in the setting of Type 2 diabetes.

Release Date:

November 28, 2011

Expiration Date:

November 28, 2013

Intended Audience:

This program is intended for all clinicians, investigators, program directors, and health care providers caring for patients with diabetes and heart disease

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

This CME activity is supported by an educational grant from sanofi-aventis U.S. Inc., A SANOFI COMPANY

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosures:

HERTZEL C. GERSTEIN, MD, MSc, FRCPC
Program Chairman
Professor & Director
Division of Endocrinology and Metabolism
McMaster-Sanofi Population Health Research Institute Chair in Diabetes
McMaster University
Head of Endocrine and Diabetes Service
Hamilton Health Sciences
Hamilton, Ontario, Canada

Consultant: sanofi-aventis, Roche, Lilly, AstraZeneca, BMS, Novo Nordisk
Grant/Research Support: sanofi-aventis, GSK, Lilly, Bayer


VIVIAN FONSECA, MD, FRCP
Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Grant/Research Support (to Tulane): Novo-Nordisk, sanofi-aventis, Eli Lilly, Daiichi-Sankyo, Pamlabs, Reata, Halozyme
Consulting and Speaking: GlaxoSmithKline, Takeda, Novo Nordisk, sanofi-aventis, Eli Lilly, Daiichi Sankyo, Pamlabs, Xoma, AstraZeneca


JORGE PLUTZKY, MD
Director, The Vascular Disease Prevention Program
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consultant: Abbott Laboratories; Amylin Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; ChemoCentryz Inc.; Daiichi Sankyo, Inc.; Genentech, Inc.;
GlaxoSmithKline; Novo Nordisk; Orexigen Therapeutics, Inc.; Roche; Takeda Pharmaceuticals North America, Inc.; Theratechnologies, Inc.


RICHARD NESTO, MD
Chair, Department of Cardiovascular Medicine
Lahey Clinic Medical Center
Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Consultant: Roche, Genentech, Merck

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewers Denise Leary and Richard Aghababian, MD have nothing to disclose.

Educational Objectives:

Upon completion of this educational activity, participating clinicians will be better able to:

• Understand the burden and challenges of cardiovascular disease in patients with T2D; and how an improved understanding of the critical interfaces among diabetes, macrovascular disease, and glycemic regulation—employing oral agents and/or insulin—can help cardiologists optimize CVD risk reduction in this vulnerable population.
• Describe the possible role of early insulin therapy for optimizing cardiovascular risk reduction across the dysglycemic continuum for T2D.
• Mitigate CV disease risk in diabetic patients with atherothrombotic heart disease using available strategies; and, optimize target goal attainment to mitigate atherthrombotic processes associated with macrovascular disease.
• Understand the molecular and inflammatory mechanisms underlying development of macrovascular disease in T2D, the role of insulin resistance, and mulitfactorial intervention in diabetes; national association-generated target goals for T2D; and multimodal strategies for glycemic control across the phenotypic spectrum of diabetes.
• Translate landmark trials in cardiovascular disease prevention in T2D to the front lines of patient care in the cardiology setting.
• Identify high-risk patients with a range of dysglycemias (IGT, elevated FBG, and overt T2D) and deploy therapies and interventions to prevent cardiovascular morbidity and mortality; and, identifying triggers for initiating or intensifying insulin treatment across the T2D dysglycemic continuum for patients with CVD.
• Understand the cardiovascular effects of thiazolidinediones (TZDs) and their relation to heart failure (HF) and myocardial infarction (MI); and, apply the clinical implications of landmark studies so that cardiovascular specialists can make best practice and evidence-based decisions to improve clinical outcomes in T2D patients with heart disease

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes.
  
  

Disclaimer:

Copyright © 2011 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2011 Resources, LLC All rights reserved